Table 3. Univariate and multivariate analyses of PFS and OS.
| Characteristics | PFS | OS | ||||
|---|---|---|---|---|---|---|
| Univariate | Multivariate | Univariate | Multivariate | |||
| p value | HR (95% CI) | p value | p value | HR (95% CI) | p value | |
| Age ≤ 60 vs. > 60 | 0.17 | 0.83 (0.60–1.16) | 0.28 | 0.003 | 0.70 (0.49–0.99) | 0.045 |
| ECOG PS 0–1 vs. ≥ 2 | 0.70 | 1.00 (0.68–1.47) | 0.99 | 0.16 | 0.86 (0.58–1.28) | 0.46 |
| CCr (mL/min) ≥ 60 vs. < 60 | 0.004 | 0.59 (0.40–0.87) | 0.008 | 0.011 | 0.72 (0.49–1.08) | 0.11 |
| Primary site UUT vs. bladder | 0.43 | 1.13 (0.83–1.52) | 0.44 | 0.56 | 0.85 (0.62–1.17) | 0.31 |
| Histologic variant VUC vs. PUC | 0.004 | 1.53 (1.10–2.15) | 0.013 | 0.007 | 1.67 (1.16–2.40) | 0.006 |
| Visceral metastasis Yes vs. No | < 0.0001 | 1.92 (1.40–2.64) | < 0.0001 | 0.009 | 1.54 (1.11–2.13) | 0.009 |
| 1st line chemotherapy Cisplatin- vs. Carboplatin-based | 0.44 | 1.48 (0.90–2.44) | 0.12 | 0.24 | 1.33 (0.81–2.18) | 0.26 |
Abbreviations: CCr, clearance of creatinine; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; OS, overall survival; PFS, progression-free survival; PS, performance status; PUC, pure urothelial carcinoma; UUT, upper urinary tract; VUC, variants of urothelial carcinoma